Skip to main content

Table 3 Treatments and outcomes of COVID-19 patients with Different BMI

From: High body mass index is a significant risk factor for the progression and prognosis of imported COVID-19: a multicenter, retrospective cohort study

Characteristics BMI < 24(Group A)
(N = 268)
BMI ≥ 24(Group B)
(N = 187)
P value
Complications
 Acute respiratory distress syndrome 7(2.6%) 15(8.0%) 0.008
 liver function abnormality 41(15.3%) 50(26.7%) 0.003
 Acute kidney injury 0(0.0%) 0(0.0%)  
 Shock 0(0.0%) 1(0.5%) 0.411
Treatments
 Antiviral treatment (n (%)) 267(99.6%) 187(100%) 0.403
  Days from illness onset to antiviral therapy (days) 5(3–8) 5(3–8) 0.926
  Days of antiviral therapy 16(13–21) 18(14–23) 0.001
 Antiviral regimen (days)    0.731
  Interferon-α + Lopinavir/Ritonavir + arbidol 159(59.6%) 120(64.2%)  
  Interferon-α + Lopinavir/Ritonavir 45(16.9%) 27(14.4%)  
  Interferon-α + arbidol 19(7.1%) 13(7.0%)  
  Lopinavir/Ritonavir+arbidol 33(12.4%) 18(9.6%)  
  Othersa 11(4.1%) 9(4.8%)  
 Supportive treatment (n (%))
  Antibiotic therapy 128(47.8%) 108(57.8%) 0.036
  Use of corticosteroid 44(16.4%) 45(24.1%) 0.043
  Use of immunoglobulin 43(16.0%) 44(23.5%) 0.046
  mechanical ventilation 2(0.7%) 6(3.2%) 0.109
  CRRT 0(0.0%) 0(0.0%)  
  ECMO 1(0.4%) 0(0.0%) 1.000
  Admission to intensive care unit 1(0.4%) 2(1.1%) 0.753
Clinical outcomes
 Days from illness onset to SARS-CoV-2 RNA negative (days) 17(13–21) 18(14–25) 0.015
 Days of hospitalization (days) 17(13–22) 19(15–24) 0.003
 Days from illness onset to discharge (days) 21(17–26) 23(18–29) 0.008
 Days of fever (days) 9(6–12) 9(6–12) 0.939
 Days from first abnormal imaging findings to obvious absorption (days) 13(10–17) 13(10–16) 0.115
  1. Data are presented as medians (interquartile ranges, IQR), n (%) and mean (SD)
  2. Othersainclude interferon-α sprays, arbidol, and lopinavir/ritonavir monotherapy
\